Implications of Introducing High-Sensitivity Cardiac Troponin T Into Clinical Practice Data From the SWEDEHEART Registry by Melki, Dina et al.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 1 6 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 2 . 0 4 4Implications of Introducing
High-Sensitivity Cardiac Troponin T
Into Clinical Practice
Data From the SWEDEHEART RegistryDina Melki, MD, PHD,* Johan Lugnegård, MD,y Joakim Alfredsson, MD, PHD,z Suzanne Lind, MD, PHD,x
Kai M. Eggers, MD, PHD,k Bertil Lindahl, MD, PHD,k Tomas Jernberg, MD, PHD*ABSTRACTFro
Sto
De
Div
Me
Me
gra
Dia
Ro
Lis
Yo
MaBACKGROUND Cardiac troponin is the preferred biomarker for diagnosing myocardial infarction (MI).
OBJECTIVES The aim of this study was to examine the implications of introducing high-sensitivity cardiac troponin T
(hs-cTnT) into clinical practice and to deﬁne at what hs-cTnT level risk starts to increase.
METHODS We analyzed data from 48,594 patients admitted because of symptoms suggesting an acute coronary
syndrome and who were entered into a large national registry. Patients were divided into Group 1, those with hs-cTnT
<6 ng/l; Group 2, those with hs-cTnT 6 to 13 ng/l; Group 3, those with hs-cTnT 14 to 49 ng/l (i.e., a group in which most
patients would have had a negative cardiac troponin T with older assays); and Group 4, those with hs-cTnT $50 ng/l.
RESULTS There were 5,790 (11.9%), 6,491 (13.4%), 10,476 (21.6%), and 25,837 (53.2%) patients in Groups 1, 2, 3, and
4, respectively. In Groups 1 to 4, the proportions with MI were 2.2%, 2.6%, 18.2%, and 81.2%. There was a stepwise
increase in the proportion of patients with signiﬁcant coronary stenoses, left ventricular systolic dysfunction, and death
during follow-up. When dividing patients into 20 groups according to hs-cTnT level, the adjusted mortality started to
increase at an hs-cTnT level of 14 ng/l.
CONCLUSIONS Introducing hs-cTnT into clinical practice has led to the recognition of a large proportion of patients with
minor cardiac troponin increases (14 to 49 ng/l), the majority of whom do not have MI. Although a heterogeneous group,
these patients remain at high risk, and the adjusted mortality rate started to increase at the level of the 99th percentile in
healthy controls. (J Am Coll Cardiol 2015;65:1655–64) © 2015 by the American College of Cardiology Foundation.C ardiac troponin (cTn) has been the recom-mended and preferred biomarker for thediagnosis of myocardial infarction (MI) since
2000 (1). Evidence of myocardial necrosis has been
deﬁned as the detection of an increase and/or
decrease of cTn with at least 1 value above the 99thm the *Department of Medicine, Section of Cardiology, Huddinge, Ka
ckholm, Sweden; yDepartment of Medical Sciences, Uppsala University
partment of Medical and Health Sciences, Linköping University, Linköp
ision of Clinical Chemistry, Karolinska Institutet, Karolinska University H
dical Sciences, Uppsala University, Uppsala, Sweden. Dr. Lindahl has serv
dical, bioMérieux Clinical Diagnostics, Philips Healthcare, Thermo-Fisher
nt from Roche Diagnostics. Dr. Eggers has received honoraria from Abbot
gnostics; and has served as a consultant for Abbott Laboratories and Fiom
che Diagnostics. All other authors have reported that they have no relations
ten to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
u can also listen to this issue’s audio summary by JACC Editor-in-Chief Dr
nuscript received January 13, 2015; accepted February 11, 2015.percentile of a normal reference population (2–4).
Guidelines also state that the assay used should
have an optimal precision (coefﬁcient of varia-
tion #10%) at this level (2–4). Due to the lack of
adequate precision of many cTn assays, a new gener-
ation of sensitive cTn assays has recently beenrolinska Institutet, Karolinska University Hospital,
, Uppsala, Sweden; zDepartment of Cardiology and
ing, Sweden; xDepartment of Laboratory Medicine,
ospital, Stockholm, Sweden; and the kDepartment of
ed as a consultant for Roche Diagnostics, Radiometer
, and Fiomi Diagnostics; and has received a research
t Laboratories, AstraZeneca, and Siemens Healthcare
i Diagnostics. Dr. Melki has received honoraria from
hips relevant to the contents of this paper to disclose.
ntin Fuster.
. Valentin Fuster.
ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome(s)
CI = conﬁdence interval
cTn = cardiac troponin
cTnT = cardiac troponin T
ECG = electrocardiogram
HF = heart failure
hs-cTnT = high-sensitivity
cardiac troponin T
MI = myocardial infarction
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1656developed to comply with guideline require-
ments (5–8). The novel ﬁfth-generation
high-sensitivity cTnT (hs-cTnT) assay, with
a validated improved analytical perfor-
mance, is a modiﬁcation of the fourth-
generation assay, lowering the decision limit
for myocardial injury from 30 ng/l (with the
fourth-generation assay) to 14 ng/l with the
ﬁfth-generation hs-cTnT assay (5).SEE PAGE 1665This new assay has a better clinical sensi-
tivity for the detection of myocardial tissueinjury, including acute MI (5–11) and is more useful
for risk stratiﬁcation compared with the fourth-
generation cTnT assay (12–22). It is, however, impor-
tant to note that the detection of cTn indicates
myocardial injury (not just ischemic injury), regard-
less of the etiology (23–25). Thus, there are concerns
that the new assays may lead to lower speciﬁcity and
perhaps unnecessary admissions and overuse of re-
sources. Consequently, it is important to describe the
clinical effects of introducing hs-cTnT into clinical
practice.
The SWEDEHEART (Swedish Web-System for
Enhancement and Development of Evidence-Based
Care in Heart Disease Evaluated According to Rec-
ommended Therapies) registry is a nationwide regis-
try that includes almost all patients who are admitted
to a coronary care unit or other specialized facility
because of symptoms suggestive of an acute coronary
syndrome (ACS) (26). The main objective of this new
study was to describe the patients who were identi-
ﬁed by the hs-cTnT assay with only a minor increase
(14 to 49 ng/l), i.e., a group in which most patients
would have had a negative result using older
cTnT assays. We evaluated baseline characteristics,
in-hospital course, ﬁnal diagnosis, and outcome.
Using a very large cohort of patients with symptoms
suggestive of an ACS, we also wanted to delineate the
association between the level of hs-cTnT and subse-
quent long-term outcome, focusing on the lower end
of the analytical range.
METHODS
For patients who are admitted to the hospital because
of symptoms suggestive of an ACS, the SWEDEHEART
registry collects information prospectively for 106
variables, including patient demographics, admission
logistics, risk factors, medical history, previous
medical treatment and investigations, medical treat-
ment in hospital, interventions, hospital outcome,
discharge diagnoses, and discharge medications (26).The SWEDEHEART registry is regularly merged with
the Swedish population registry, which includes in-
formation about the vital status of all Swedish
citizens. To ensure the correctness and high quality
of the registry data, hospitals are monitored on a
regular basis. The degree of agreement between
the hospital records and the registry is 96% (26).
Patients included in the registry are informed
about their participation and maintain the right to
decline (26).
STUDY POPULATION. The study included a total of
48,594 consecutive patients who, over a 4-year
period (2009 to 2012), were admitted and recorded in
the SWEDEHEART registry in 45 Swedish hospitals
that had introduced the hs-cTnT assay into their
clinical practice. Only centers with more than 100
registered patients with measured hs-cTnT were
included. An acute MI was deﬁned according to cur-
rent guidelines (2,3), and all hospitals used the 99th
percentile in healthy controls as decision limits.
However, 8 hospitals initially used higher (30 to
40 ng/l) decision limits. All data were made anony-
mous before statistical analyses were performed. The
study was conducted according to the principles of
the Declaration of Helsinki and approved by the local
ethics committee.
LABORATORY ANALYSIS. The Elecsys troponin T
high-sensitive assay (Roche Diagnostics Corporation,
Indianapolis, Indiana) was used to determine the
maximal hs-cTnT level during hospitalization. The
recommended limit of blank and limit of detection
of hs-cTnT are 3 ng/l and 5 ng/l, respectively (5). The
99th percentile in healthy controls is 14 ng/l (27),
and the coefﬁcient of variation (#10%) is reached at
13 ng/l (5). The analytical range of measurement is
3 to 10,000 ng/l (5,27). Recently, 2 studies (5,27)
demonstrated that cTn concentrations determined
by the fourth-generation cTnT and hs-cTnT assay are
not comparable at the lower end of the analytical
range. Giannitsis et al. (5) showed that a cTn value of
30 ng/l according to the fourth-generation cTnT
assay corresponds to w50 ng/l according to the
hs-cTnT assay. This has also been supported by
others (27); therefore, we divided our study popu-
lation into 4 groups according to the maximal
hs-cTnT during hospitalization: Group 1 with a
maximal hs-cTnT value <6 ng/l (a test result below
the limit of detection [<5 ng/l] has, in the majority
of cases, been registered as “5” ng/l in the registry);
Group 2 with a maximal hs-cTnT value of 6 to
13 ng/l; Group 3 with a maximal hs-cTnT value of 14
to 49 ng/l (i.e., a group in which most patients
would have had a negative cTnT using the old cTnT
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1657assay); and, last, Group 4 with an hs-cTnT maximal
value of $50 ng/l (i.e., a group in which most pa-
tients would have had a positive cTnT result even if
the old cTnT assay had been used).
The study population was further divided into
4 groups according to main (primary) diagnosis at
discharge: 1) ACS (acute MI and unstable angina pec-
toris); 2) other cardiac diseases (e.g., myocarditis,
atrial ﬁbrillation); 3) other noncardiac or unknown
diseases; and 4) heart failure (HF). To examine the
relationship between maximal hs-cTnT and all-cause
mortality, patients were further subdivided accord-
ing tomaximal hs-cTnT level into 10 to 20 equally large
groups (except for the group with no measurable hs-
TnT [<6 ng/l], which could not be further divided).
Glomerular ﬁltration rates were calculated using the
Chronic Kidney Disease Epidemiology Collaboration
equation (28). Follow-up of patients to assess all-cause
mortality was done at 1 year from admission.
STATISTICAL ANALYSIS. Categorical variables were
summarized as numbers and percentages, and con-FIGURE 1 Summary of the Study Population
Group 1
hs-cTnT < 6 ng/L
5,790 patients
Group 2
hs-cTnT 6-13 ng/L
6,491 patients
Study pop
48,594 p
SWEDEH
2009-2
MI (n,%)
128 (2.2) patients
UAP (n,%)
1,629 (28.3) patients
Mortality at 1 year (n,%)
95 (1.6) patients
MI (n,%)
169 (2.6) patients
UAP (n,%)
2,956 (45.7) patients
Mortality at 1 year (n,%)
158 (2.4) patients
Number of patients with different levels of high-sensitivity cardiac trop
infarction; UAP ¼ unstable angina.tinuous data by median (interquartile range). Cate-
gorical variables were analyzed using the chi-square
test and continuous variables were compared using
the Kruskal-Wallis test.
A multivariable Cox proportional hazards model,
using the group with maximal hs-cTnT <6 ng/l (i.e.,
no measurable hs-cTnT) as the reference group,
was used to assess the adjusted association between
maximal hs-cTnT and all-cause mortality for all
patients and in 4 groups according to the main
diagnosis at discharge. Factors included in the
model were age, male, smoking, hypertension, dia-
betes mellitus, previous HF, previous MI, previous
stroke, previous percutaneous coronary inter-
vention, previous coronary artery bypass grafting,
sinus rhythm on the admission electrocardiogram
(ECG), atrial ﬁbrillation/ﬂutter on the admission
ECG, ST-segment depression on the admission ECG,
ST-segment elevation on the admission ECG,
percutaneous coronary intervention during hospi-
talization, coronary artery bypass grafting during
hospitalization, and glomerular ﬁltration rate.Group 3
hs-cTnT 14-49 ng/L
10,476 patients
Group 4
hs-cTnT ≥ 50 ng/L
25,837 patients
ulation
atients
EART
012
MI (n,%)
1,902 (18.2) patients
UAP (n,%)
4,537 (43.5) patients
Mortality at 1 year (n,%)
1,078 (10.3) patients
MI (n,%)
20,774 (81.2) patients
UAP (n,%)
2,140 (8.4) patients
Mortality at 1 year (n,%)
4,422 (17.1) patients
onin T (hs-cTnT) and subsequent 1-year mortality. MI ¼ myocardial
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version 20 software (IBM Corp., Armonk, New York).
RESULTS
BASELINE CHARACTERISTICS. There were 5,790
patients (11.9%) with a maximal hs-cTnT <6 ng/l
(Group 1), 6,491 (13.4%) with a maximal hs-cTnT of
6 to 13 ng/l (Group 2), 10,476 (21.6%) with a maximal
hs-cTnT of 14 to 49 ng/l (Group 3), and 25,837 (53.2 %)
patients with a maximal hs-cTnT $50 ng/l (Group 4)
(Figure 1). Baseline characteristics in relation to
hs-cTnT level are shown in Table 1. When baseline
characteristics were compared, Group 3 was similar to
Group 4 with regard to age, sex, and the presence ofTABLE 1 Baseline Characteristics
<6 ng/l
(n ¼ 5,790)
6–13 n
(n ¼ 6,4
Age, yrs 58 (48–66) 66 (58–
Male 2,991 (51.7) 3,976 (61.3
Risk factors
Smoking 1,167 (20.2) 967 (14.9
Diabetes mellitus 693 (12) 1,211 (18.7
Hypertension 2,131 (36.9) 3,322 (51.3
Previous cardiovascular disease
Myocardial infarction 1,250 (21.7) 2,226 (34.
Heart failure 272 (4.7) 658 (10.
Stroke 244 (4.2) 476 (7.4
PCI 1,194 (20.7) 2,019 (31.2
CABG 308 (5.3) 740 (11.4
Medication on admission
Aspirin 2,141 (37.1) 3,315 (51.2
P2Y12 receptor blocker 536 (9.3) 953 (14.7
Beta-blocker 2,192 (38) 3,397 (52.5
Statin 2,069 (35.9) 3,163 (48.
ACEI/ARB 1,747 (30.3) 2,957 (45.
Cardiogenic shock at admission 7 (0.1) 18 (0.3
Main reason for presentation
Chest pain 5,020 (87) 5,591 (86.
Dyspnea 167 (2.9) 231 (3.6
Cardiac arrest 8 (0.1) 15 (0.2
Other* 574 (9.9) 603 (9.4
Electrocardiography
Sinus rhythm 5,315 (92.1) 5,582 (86.
Atrial ﬁbrillation/ﬂutter 350 (6.1) 670 (10.
ST-segment depression 582 (10.1) 714 (11.1
ST-segment elevation 302 (5.3) 355 (5.5)
Systolic blood pressure, mm Hg 145 (130–160) 149 (131
Diastolic blood pressure, mm Hg 82 (75–92) 82 (73–
Heart rate, beats/min 74 (64–86) 72 (63–
GFR, ml/min 91.3 (78.7–101.4) 82.7 (68.
Values are median (interquartile range) or n (%), unless otherwise indicated. *Include s
dyspnea, such as nausea, abdominal discomfort, and general malaise.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blo
hs-cTnT ¼ high-sensitivity cardiac troponin T; PCI ¼ percutaneous coronary interventionrisk factors. Comparedwith Group 4, Group 3 hadmore
patients with previous cardiac disease (such as previ-
ous MI, revascularization, and HF) and atrial ﬁbrilla-
tion/ﬂutter on admission, and, consequently, these
patients were more often treated with antiplatelet
therapy, beta-blockers, statins, and angiotensin-
converting enzyme inhibitors, or angiotensin recep-
tor blockers. With increasing levels of maximal
hs-cTnT, there was an increase in the proportion of
patients presenting with ST-segment deviation.
Characteristics of the patients during hospitaliza-
tion are shown in Table 2. When Groups 1, 2, 3, and 4
were compared, there was a stepwise increase in the
use of coronary angiography and echocardiography.
In patients who underwent coronary angiography,hs-cTnT
p Value
g/l
91)
14–49 ng/l
(n ¼ 10,476)
$50 ng/l
(n ¼ 25,837)
74) 73 (64–81) 72 (63–81) <0.001
) 6,671 (63.7) 16,774 (64.9) <0.001
) 1,331 (12.7) 4,923 (19.1) <0.001
) 2,680 (25.7) 6,050 (23.5) <0.001
) 5,948 (57) 13,238 (51.3) <0.001
4) 4,227 (40.5) 8,038 (31.2) <0.001
2) 1,830 (17.5) 3,437 (13.3) <0.001
) 1,094 (10.5) 2,647 (10.3) <0.001
) 3,058 (29.3) 4,623 (17.9) <0.001
) 1,696 (16.2) 2,924 (11.3) <0.001
) 5,451 (52.2) 10,949 (42.5) <0.001
) 1,526 (14.6) 2,615 (10.1) <0.001
) 5,861 (56.2) 11,083 (43) <0.001
9) 5,126 (49.1) 9,235 (35.8) <0.001
7) 5,350 (51.3) 10,298 (39.9) <0.001
) 39 (0.4) 284 (1.1) <0.001
8) 8,046 (77.5) 20,307 (79.1) <0.001
) 1,091 (10.5) 2,565 (10.0) <0.001
) 40 (0.4) 466 (1.8) <0.001
) 1,200 (11.6) 2,333 (9.1) <0.001
6) 7,870 (75.7) 21,274 (82.8) <0.001
4) 1,914 (18.4) 3,322 (12.9) <0.001
) 1,676 (16.2) 5,902 (23) <0.001
564 (5.4) 7,328 (28.5) <0.001
–165) 149 (130–167) 145 (125–165) <0.001
91) 80 (70–90) 82 (70–95) <0.001
85) 76 (65–92) 80 (68–97) <0.001
5–93.3) 70.7 (53.6–85.9) 71.2 (50.5–87.7) <0.001
ymptoms suggestive of possible acute coronary syndrome other than chest pain and
cker; CABG ¼ coronary artery bypass grafting; GFR ¼ glomerular ﬁltration rate;
.
TABLE 2 In-Hospital Course
hs-cTnT
p Value
<6 ng/l
(n ¼ 5,790)
6-13 ng/l
(n ¼ 6,491)
14-49 ng/l
(n ¼ 10,476)
$50 ng/l
(n ¼ 25,837)
Coronary angiography 1,419 2,247 4,808 18,017
Nonconclusive 2 (0.1) 8 (0.4) 19 (0.4) 59 (0.3) 0.533
Normal/atheromatosis 806 (56.8) 876 (39.0) 1,373 (28.6) 2,157 (12.0) <0.001
1–2 VD 456 (32.1) 924 (41.1) 2,222 (46.2) 10,684 (59.3) <0.001
LM or 3 VD 155 (10.9) 439 (19.5) 1,194 (24.8) 5,117 (28.4) <0.001
Echocardiography (LVEF) 2,122 2,474 5,157 18,613
Normal, $50% 1,913 (90.2) 2,088 (84.4) 3,626 (70.3) 10,243 (55.0) <0.001
Mild/moderate dysfunction, 31%–49% 186 (8.8) 334 (13.5) 1,124 (21.8) 6,867 (36.9) <0.001
Severe dysfunction, #30% 23 (1.1) 52 (2.1) 407 (7.9) 1503 (8.1) <0.001
Treatment
IV UFH, LMWH, or fondaparinux 1,123 (19.6) 1,652 (25.7) 4,295 (41.2) 15,428 (59.8) <0.001
IV beta-blocker 145 (2.5) 232 (3.6) 613 (5.9) 2,996 (11.6) <0.001
IV diuretic agent 102 (1.8) 251 (3.9) 1,461 (14.0) 6,159 (23.9) <0.001
IV inotropic agent 6 (0.1) 23 (0.4) 94 (0.9) 1,066 (4.1) <0.001
IV nitroglycerin 227 (4) 373 (5.8) 663 (6.4) 3,212 (12.5) <0.001
CPAP 16 (0.3) 26 (0.4) 194 (1.9) 1,477 (5.7) <0.001
Interventions
PCI 490 (8.5) 986 (15.2) 2,421 (23.1) 12,708 (49.2) <0.001
CABG 86 (1.5) 209 (3.2) 411 (3.9) 1,457 (5.6) <0.001
Complications
Cardiogenic shock 2 (0.0) 9 (0.1) 54 (0.5) 511 (2.0) <0.001
Cardiac arrest 7 (0.1) 16 (0.2) 65 (0.6) 626 (2.4) <0.001
Atrial ﬁbrillation 83 (1.4) 130 (2) 346 (3.3) 1,284 (5.0) <0.001
Medication at discharge (survivors)
Aspirin 2,683 (47.9) 3,980 (63.5) 7,170 (71.0) 21,310 (88.0) <0.001
P2Y12 receptor blocker 917 (16.4) 1,751 (27.9) 3,946 (39.1) 17,414 (71.9) <0.001
Warfarin 397 (7.1) 810 (12.9) 1,956 (19.4) 2,457 (10.1) <0.001
Beta-blocker 2,743 (49) 4,131 (65.9) 7,798 (77.2) 20,950 (86.5) <0.001
Statin 2,653 (47.4) 3,998 (63.8) 7,008 (69.4) 20,054 (82.8) <0.001
ACEI/ARB 2,071 (37) 3,459 (55.2) 6,703 (66.4) 18,159 (75) <0.001
Diagnosis at discharge
ACS 1,757 (30.5) 3,125 (48.3) 6,439 (61.7) 22,914 (89.6) <0.001
Myocardial infarction 128 (2.2) 169 (2.6) 1,902 (18.2) 20,774 (81.2) <0.001
Unstable angina pectoris 1,629 (28.3) 2,956 (45.7) 4,537 (43.5) 2,140 (8.4) <0.001
Heart failure 71 (1.2) 141 (2.2) 688 (6.6) 699 (2.7) <0.001
Other cardiac disease 581 (10.1) 715 ( 11.1) 1,270 (12.2) 1,129 (4.4) <0.001
Unknown or other noncardiac disease 3,357 (58.2) 2,488 (38.5) 2,035 (19.5) 851 (3.3) <0.001
Values are n (%).
ACS ¼ acute coronary syndrome(s); CPAP ¼ continuous positive airway pressure; IV ¼ intravenous; LM ¼ left main; LMWH ¼ low-molecular weight heparin;
LVEF ¼ left ventricular ejection fraction; UFH ¼ unfractionated heparin; VD ¼ vessel disease; other abbreviations as in Table 1.
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1659signiﬁcant stenoses were present in 43.0%, 60.6%,
71.0%, and 87.7%, and in patients who underwent
echocardiography, any left ventricular systolic
dysfunction was present in 9.9%, 15.6%, 29.7%, and
45.0% in Groups 1, 2, 3, and 4, respectively. There was
also a stepwise increase in the use of different intra-
venous treatments, use of continuous positive airway
pressure, coronary interventions, complications, and
use of different post-ACS medications at discharge.
In Groups 1 and 2, the most common diagnoses
(58.2% and 38.5%) were unknown or other noncardiac
causes, whereas ACS was considered present in 30.5%and 48.3%, respectively. In Group 3, 61.7% were
considered to have an ACS, of whom 18.2% had a
diagnosis of MI. In Group 4, a majority (89.6%) had a
diagnosis of an ACS, including 81.2% with MI.
MORTALITY IN RELATION TOTROPONIN CONCENTRATION.
Follow-up of patients for all-cause mortality was
done at 1 year from admission. There were 95 (1.6%),
158 (2.4%), 1,078 (10.3%), and 4,422 (17.1%) deaths in
Groups 1, 2, 3, and 4, respectively (Figure 1).
Compared with Group 1, the adjusted hazard ratios
were 1.07 (95% conﬁdence interval [CI]: 0.81 to 1.41;
p ¼ 0.66), 2.53 (95% CI: 2.00 to 3.21; p < 0.001), and
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16604.65 (95% CI: 3.68 to 5.88; p < 0.001) in Groups 2, 3,
and 4, respectively. When the study population was
divided into 20 groups according to maximal hs-cTnT
levels, crude mortality started to increase at an
hs-cTnT level of 12 to 13 ng/l (Figure 2A), whereas
adjusted mortality started to increase at an hs-cTnT
level of 14 to 18 ng/l (hazard ratio: 1.94; 95% CI: 1.47
to 2.56; p < 0.001) (Figure 2B). At levels higher than 14
ng/l, the adjusted mortality increased continuously
with increasing hs-cTnT.
The pattern was similar in men and women and in
those younger or older than 65 years of age, but with a
somewhat higher crude mortality rate in women and
much higher mortality rate in the elderly (Figures 2C
and 2D).
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DISCUSSION
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CENTRAL ILLUSTRATION Mortality in Relation to Discharge Diagnosis
This study examined the implications of introducing high-sensitivity cardiac troponin T (hs-cTnT) as a biomarker into clinical practice and to deﬁne at what
hs-cTnT level risk starts to increase. When study patients were divided according to the primary discharge diagnosis, there was an association seen between
crude (top) and adjusted (bottom) all-cause mortality and level of hs-cTnT. HR ¼ hazard ratio.
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1662that 1 in 5 (21.6%) had a minor increase in troponin
(hs-cTnT 14 to 49 ng/l), a groupwhomay not have been
identiﬁed by the previous fourth-generation cTnT
assay. Our results indicate that the new hs-cTnT assay
identiﬁes a large and important subgroup of previously
cTn-negative patients.
With regard to demographics and the presence
of risk factors, patients with maximal hs-cTnT
14 to 49 ng/l were similar to those with maximal
hs-cTnT $50 ng/l. The prevalence of previous car-
diovascular diseases was even higher in patients with
minor increase in hs-cTnT than in patients with a
major increase in hs-cTnT. This is probably explained
by a greater proportion of patients with chronically
increased troponin levels in the former group.
Compared with patients with hs-cTnT <14 ng/l, pa-
tients with hs-cTnT 14 to 49 ng/l more often had
signiﬁcant stenoses at coronary angiography and
depressed left ventricular systolic dysfunction.
Accordingly, the latter group was treated more
aggressively with antithrombotic treatment and cor-
onary interventions. It is, however, important to note
that only 18.2% of those with minor increases in
hs-cTnT (14 to 49 ng/l) were diagnosed with MI. The
majority were considered to have unstable angina
pectoris (43.5%) or no ACS at all (38.3%), which may
indicate a large proportion of patients with a lack of
an increase and/or decrease in troponin levels or
other reasons for increased troponin.
Our study shows an increase in all-cause mortality
with increasing maximal hs-cTnT levels regardless of
the cause of troponin increase (Central Illustration). A
large number of studies involving similar populations
have shown an increased mortality with increasing
levels of cTn irrespective of the etiology of the cTn
increase. Jolly et al. (29) used the GRACE registry
(Global Registry of Acute Coronary Events) for risk
evaluation of patients with non–ST-segment eleva-
tion ACS in relation to cTn values (29). Peak values of
cTn were used in their analysis as in our study. In the
study from Jolly et al. (29), which included 16,318
patients and used old cTn assays (cTn T or I), the
extent of cTn increase was independently associated
with all-cause mortality (29). Irfan et al. (20) showed
that patients who presented at an emergency
department with a noncardiac cause of chest pain but
with hs-cTnT values >14 ng/l had a higher all-cause
mortality compared with patients with hs-cTnT #14
ng/l. In a study by de Lemos et al. (30), which eval-
uated a general apparently healthy population,
hs-cTnT (cutoff 14 ng/l) was detectable in 25% of the
population and associated with all-cause mortality.
By using a new generation of sensitive troponin
assays, troponin increases can be detected in morepatients, leading to better risk assessment. Celik et al.
(31), Aldous et al. (12), Hochholzer et al. (13), and
Haaf et al. (32) showed that hs-cTnT outperformed
contemporary cTn assays in predicting mortality
(13,31,32) or major adverse cardiac event rate (com-
posite of cardiovascular death, nonfatal MI, and
revascularization) (12). Mueller et al. (14) also showed
that hs-cTnT outperformed cardiac troponin I
(using the Centaur TnI-Ultra immunoassay system,
Siemens Corporation, Munich, Germany) in predicting
all-cause mortality in patients with a suspected ACS.
Pascual-Figal et al. (16) demonstrated that hs-cTnT
performed better than fourth-generation cTnT assays
in predicting death in patients with decompensated
HF. The aforementioned studies used 99th percentile
of healthy controls as the cutoff value. By using a very
large sample, we were able to divide patients into
20 different groups according to maximal hs-cTnT
level. In the adjusted analyses, there was no increase
in mortality in patients with hs-cTnT <14 ng/l. There
was no obvious difference between men and women
in terms of the level of cTn at which risk started
to increase.
STUDY LIMITATIONS. The SWEDEHEART includes
mainly patients admitted to a coronary care unit
because of an intermediate or high level of suspi-
cion of an ACS. This explains the fairly high prev-
alence of risk factors and previous cardiovascular
disease in patients with hs-cTnT <14 ng/l. Data
used in this analysis were collected in a registry.
Although all participating hospitals are monitored
regularly, and the agreement between the hospital
records and the registry has repeatedly been found
to be 96% (26), the data cannot be of the same
quality as in a clinical prospective, observational
study. This is particularly the case when it comes to
a recently introduced biomarker, such as hs-cTnT,
measured as nanograms per liter instead of the
previously used micrograms per liter. In this study,
2.4% of all patients with a maximal hs-cTnT
<14 ng/l eventually received a diagnosis of MI.
These “troponin-negative” MIs are most likely due
to erroneous registrations of hs-cTnT values. How-
ever, the potential effects of this bias on the overall
results are small. In the registry, only the maximal
hs-cTnT value has been registered, and we have
therefore been unable to differentiate between pa-
tients with dynamic changes of hs-cTnT and those
without. The maximal value also may be inﬂuenced
by blood sampling strategies that may vary between
hospitals. The diagnoses were set by the discerning
physicians and not further adjudicated. Finally, we
did not include cause of death. However, most
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In an unselected
high-risk population, a hs-cTnT assay identiﬁed a large propor-
tion of patients with minor troponin increases (14 to 49 ng/l) not
detected using the previous, less sensitive assay. Patients with
minor cTnT increases face an increased risk of future ischemic
events.
TRANSLATIONAL OUTLOOK: More studies are needed to
characterize the heterogeneity of patients with minor cTnT
increases, to expose underlying pathophysiological mechanisms
responsible for low-level troponin release, and to enhance
treatment strategies to improve long-term clinical outcomes.
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1663deaths after an episode of ACS are cardiovascular
in nature, and the validity of death certiﬁcates is
limited.
CONCLUSIONS
In a nonselected high-risk population, the introduc-
tion of hs-cTnT has led to the identiﬁcation of a large
proportion of patients with minor cTn increases (14 to
49 ng/l), a group in which most patients would have
had a negative cTnT if the old cTnT assay had
been used. The majority of patients with a minor cTn
increase did not receive diagnosis of experiencing an
MI but were still at high risk. After adjusting for dif-
ferences in baseline characteristics, long-term mor-
tality starts to increase at the level of the 99th
percentile in healthy controls (14 ng/l); there then is
seen a stepwise increase in mortality with increasing
levels of hs-cTnT, regardless of the underlying cause
of cTn increase.
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